Clinical relevance of patient-reported outcomes: new threshold proves to be practical

18 February 2021 - Current examples show that the 15% threshold newly set by IQWiG for the recognition of responder analyses ...

Read more →

Germans turn backs on AstraZeneca vaccine

22 February 2021 - Germany’s vaccination program is in trouble, with people failing to keep appointments if they are going ...

Read more →

Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR

4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...

Read more →

From publication bias to lost in information

11 December 2020 - In BMJ Evidence-Based Medicine, IQWiG researchers call for a central, public and worldwide portal for clinical ...

Read more →

Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries

10 December 2020 - Zisis and colleagues performed a literature review to identify published guidance for the conduct and assessment ...

Read more →

Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment

3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible. ...

Read more →

IQWiG publishes 1,000th report

2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...

Read more →

Trifarotene in moderate acne: no study data for the assessment of the added benefit

16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...

Read more →

IQWiG publishes a new version of its general methods

5 November 2020 - New features include the investigation of volume-outcome relationships and different mean observation times in clinical studies. ...

Read more →

Fostamatinib in chronic immune thrombocytopenia: added benefit not proven due to lack of comparison

1 October 2020 - Only placebo controlled studies in the dossier. ...

Read more →

Germany has not fully realised its biosimilar potential

29 September 2020 - Investigators have concluded that fully realizing the cost-saving potential of biosimilars could “release enormous resources” for ...

Read more →

Second joint meeting on ‘Innovations in Healthcare’

18 September 2020 - How can methodological and scientific advice to manufacturers of medicinal products be further optimised at European level ...

Read more →

The best possible security of supply for cancer therapy with CAR-T cells

17 September 2020 - Medical facilities that treat patients with novel cell therapies (CAR-T cells) must meet newly defined quality requirements. ...

Read more →

Talazoparib in breast cancer: hint of considerable added benefit

1 September 2020 - Advantages in health related quality of life, symptoms and side effects outweigh disadvantages. ...

Read more →

Mylan, Lupin launch etanercept biosimilar in Germany

26 August 2020 - The launch marks the first European market entry for Nepexto. ...

Read more →